Cell-based therapies with autologous adipose tissue–derived cells have shown great potential in several clinical studies in the last decades.The majority of these studies have been using the stromal vascular fraction (SVF), a heterogeneous mixture of fibroblasts, lymphocytes, monocytes/macrophages, endothelial cells, endothelial progenitor cells, pericytes and adipose-derived stromal/stem cells (ASC) among others. Although possible clinical applications of autologous adipose tissue derived cells are manifold, they are limited by insufficient uniformity in cell identity and regenerative potency.
